Candel Therapeutics, Inc. (CADL)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $512.23M
- P/E ratio
- —
- EPS
- —
- Volume
- 1,110,161
- 52-week high
- —
- 52-week low
- —
- Open
- $10.19
- Day high
- $10.59
- Day low
- $9.55
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$38.18M | -$0.72 |
| 2024 | — | -$55.18M | -$1.74 |
| 2023 | — | -$37.94M | -$1.31 |
| 2022 | $125K | -$18.79M | -$0.65 |
| 2021 | $125K | -$36.12M | -$1.91 |
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
- CEO
- Paul-Peter Tak
- Employees
- 55
- Country
- US
- IPO date
- Jul 27, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Candel Therapeutics, Inc.'s stock price today?
- CADL is trading at $9.57 as of Jul 20, 2026.
- What is Candel Therapeutics, Inc.'s market cap?
- Candel Therapeutics, Inc. (CADL) has a market capitalization of $512.23M.
- Does Candel Therapeutics, Inc. pay a dividend?
- Candel Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Candel Therapeutics, Inc. in?
- Candel Therapeutics, Inc. operates in the Healthcare sector.